Breaking Corporate Events, Analysed in Real Time

Lupin Reports Record ₹27,958 Cr Revenue in FY26; US Business Surges 40 Percent

Lupin achieved record-breaking financial performance in FY26, driven by a 40% surge in its US business and steady growth in India's chronic segment. The company handsomely beat its margin guidance, reporting an EBITDA margin of 29.7% against an original expectation of 27-28%.

Lupin Limited Reports 32% Q4 Revenue Growth as FY26 EBITDA Surges 68%

Lupin Limited delivered a record-breaking performance in FY26, characterized by significant surges in US generic sales and a robust prescription business in India. While the company exceeded margin guidance for the year, management has signaled a more conservative stance for FY27 to account for upcoming competitive pressures in key product categories.